Not Yet Recruiting EARLY_PHASE1 INTERVENTIONAL 2-arm
NCT06782399
Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma (SCC)
A Pilot of a Microdevice for in Situ Candidate Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
Sponsor: Dana-Farber Cancer Institute
Interventions
Microdevice
Updated 1 time since 2025 Last updated: Jan 14, 2025 Started: Jul 31, 2025 Primary completion: Jul 31, 2028 Completion: Jul 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06782399, this EARLY_PHASE1 trial focuses on Squamous Cell Carcinoma and Squamous Cell Carcinoma of the Skin and remains actively recruiting participants. Sponsored by Dana-Farber Cancer Institute, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — EARLY_PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Dana-Farber Cancer Institute
- Oliver Jonas
Data source: Brigham and Women's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.